The Us Drug Major Eli Lilly Is Fighting A Patent Infringement Litigation Against Several Indian Companies For The Intellectual Property Rights On Its Compound Baricitinib, Even Though It Has Issued Eight Royalty-Free Voluntary Licenses To Indian Pharmaceutical Companies To Distribute The Drug Solely For Treatment Of Covid-19, A Few Months Back. Eli Lilly Sells The Drug Under The Brand Olumiant.The Company Has Filed A Complaint At The Delhi High Court Against Almost 20 Entities Or Individuals For Allegedly Marketing And Advertising Sale Of Barinat - The Brand Name Under Which Hyderabad-Based Natco Manufactures And Markets Baricitinib - As A Treatment For Rheumatoid Arthritis. Eli Lilly Announced In May This Year That It Has Entered Into A Royalty-Free Voluntary License Agreement With Natco, Only For The Treatment Of Covid-19.Eli Lilly Argued That The Alleged Marketing And Advertising Of The Product For Another Ailment Is
